Clinical Trials Using NY-ESO-1 Peptide Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying NY-ESO-1 Peptide Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • A Phase I Study of WT1 or NY-ESO-1 OLP4 Vaccine and Nivolumab For the Treatment of Recurrent Ovarian Cancer

    This phase I trial studies the side effects of nivolumab in combination with Wilms tumor 1 (WT1) vaccine or New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) protein overlapping long peptides (OLP4) vaccine in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) at least twice and is now in remission. Vaccines made from WT1 and NY-ESO-1 peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent. Montanide and Poly-ICLC have been shown to increase the effect of vaccines on the immune system. Giving WT1 or NY-ESO-1 vaccine together with nivolumab may work better in treating ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 7 locations